Bayer is a life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are helping find solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.
Edwards Lifesciences, based in Irvine, California, is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures, including an estimated $79.6 billion in 2018 alone.
Novartis is re-imagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company develops, manufactures and markets pharmaceutical products for precision patient care and strives to help patients around the world with severe and chronic diseases lead better, healthier lives. It consists of the following companies: Vifor Pharma; the joint company Vifor Fresenius Medical Care Renal Pharma; Relypsa; and OM Pharma.
Bayer China Ltd. is an innovation company with a more than 150-year history with core competencies in the life science fields of health care and nutrition. With our innovative products, we are helping find solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Amgen focuses on areas of high unmet medical need strives for solutions that improve health outcomes and dramatically improve people’s lives. It has grown to be one of the world’s leading biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Set up in 2009 at the Università Cattolica del Sacro Cuore (Rome campus) as a result of a scientific collaboration between the faculty of Economics and the faculty of Medicine and Surgery, ALTEMS operates within the field of Economics and Healthcare management and offers qualification-based training at various stages in the professional development of people employed in the field of private and public healthcare. The mission of ALTEMS, in which its fundamental purposes are stated, is “to plan, organise and deliver post-graduate and executive training programmes within the fields of economics and health care management.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life
Health Technology Wales has been established to support a strategic, national approach to the identification, appraisal and adoption (including disinvestment) of non-medicine health technologies into health and care settings. This includes medical devices, surgical procedures & a range of other interventions e.g. psychological therapies & rehabilitation.
HTW is an independent, arms-length organisation that will deliver authoritative evidence-informed advice about the value for money of non-medicine health technologies to improve patient outcomes for all patients in Wales.
HTWs works in three main areas – identification, appraisal and adoption of non-medicine technologies – to help create a common understanding of value in NHS Wales and to optimise the use of health interventions.
To deliver these functions HTW is working with health, academic, patient and industry bodies in Wales and internationally.
Family-owned since 1885, Boehringer Ingelheim is one of the top 20 pharmaceutical companies worldwide.
Some 50,000 employees create value through innovation in the business areas human pharmaceuticals, animal health and biopharmaceuticals. In our role as our patients’ partner we concentrate on researching and developing innovative medicines and therapies that can improve and extend patients’ lives.